martedì 19 maggio 2020

FDA Grants Accelerated Approval to Rucaparib for BRCA-mutated Metastatic Castration-Resistant Prostate Cancer - Evidence for efficacy is based on the results from the TRITON2 study

Fonte: ESMO European Society for Medical Oncology

Link all'articolo completo